Aaron Goldman
Director - Faculty & Instructor in Medicine Harvard Medical School
Aaron is an Operating Partner at BroadOak where he supports the firm’s investing activities, diligence, and portfolio companies focused on complex biological models and cell therapy.
Prior to BroadOak, Aaron held senior positions at clinical-stage therapeutics companies and led product development R&D at several biotools companies focused on oncology. Aaron founded and served as CEO of Transporter Therapeutics, an AstraZeneca-partnered start-up company, that he led to an exit in 2022. Aaron has written over 80 scientific and research publications and is an author on 12 patents and patent applications related to drug development and diagnostics platforms.
Aaron is an active faculty member at Harvard Medical School, a member of Cancer Immunology at the Dana-Farber Cancer Institute. He is also the founder of the Drug Resistance Group at Mass General Brigham. He received his Ph.D. in Cancer Biology and Medical Pharmacology from the University of Arizona and performed his post-doctoral fellowship at Harvard Medical School.
Seminars
With iPSC therapies facing high upfront costs, complex manufacturing demands, and evolving investor sentiment, early alignment across pharma, VCs, and funding stakeholders is critical. This panel will explore how to strategically de-risk clinical development, secure funding, and build commercially viable cell therapy programs in a capital-intensive landscape.
- How to engage pharma BD, VCs, and payers early to overcome the “elephant in the room”, high cost of goods and long development timelines
- What investors look for in scalable, robust iPSC manufacturing strategies before committing capital
- Coordinating government funding, venture investment, and pharma partnerships to support sustainable clinical and commercial success
